Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    In-Person

    What is this Study about?

    It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.

    Eligibility Criteria

    You are eligible to participate if you meet the following criteria:

    • Age ≥ 55; females must be post-menopausal

    • DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)

    • sMMSE ≤ 24

    • Clinically significant agitation based on IPA definition

    • Stable cognition-enhancing medication for at least 3 months prior to study enrolment

    • Availability of a caregiver to accompany participant to study visits and to participate in the study

    • Ability to speak English

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.

    Eligibility Criteria

    Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.

    Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.

    Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.

    Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.

    Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.

    Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.

    Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.

    Have not undergone any significant head trauma or surgery in the past 6 months.

    Are not pregnant or planning to become pregnant during the duration of the study.

    Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.

    Ability to speak English and French

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    The study is aiming to assess whether nutritional intervention with personalized, preselected prebiotics can affect cognitive function in those with Alzheimer’s disease. This study is placebo-controlled, and participants will be randomized to either the placebo or prebiotic.

    Eligibility Criteria

    • Aged 60 or older
    • Diagnosis of Mild Cognitive Impairment, Alzheimer’s disease, or Amnestic Mild Cognitive Impairment
    • Has someone who can be their study partner

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    We want to determine if a nutrition questionnaire (SCREEN) works well to identify nutrition challenges for older adults with diagnosed memory problems, cognitive impairment or dementia when completed by themselves, or by a care partner on behalf of their cared for person.

    Eligibility Criteria

    You may be eligible if you are:

    • 55 years or older

    • Read/speak English

    • Live within 45km of Waterloo, Guelph or London.

    AND are an:

    • Older adult with diagnosed memory problems, cognitive impairment or dementia with a care partner who either lives with you, or who is in daily contact with you and would be able to support reporting of their eating behaviours

    • If living in a retirement home, the older adult must have lived in their home for at least 3 months and receive 2 or more meals each day from their retirement home

    Recruitment End Date